<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01405079</url>
  </required_header>
  <id_info>
    <org_study_id>CTONG 1104</org_study_id>
    <secondary_id>CTONG 1104</secondary_id>
    <nct_id>NCT01405079</nct_id>
  </id_info>
  <brief_title>Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation</brief_title>
  <acronym>ADJUVANT</acronym>
  <official_title>A Randomized, Open-label Trial of Gefitinib Versus Combination of Vinorelbine Plus Platinum as Adjuvant Treatment in Pathological Stage II-IIIA(N1-N2) Non-small Cell Lung Cancer With EGFR Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Association of Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangdong General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jilin Provincial Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaoning Tumor Hospital &amp; Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of China Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>309th Hospital of Chinese People's Liberation Army</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qingdao University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangsu Cancer Institute &amp; Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tang-Du Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangdong Association of Clinical Trials</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Activating somatic mutations of the tyrosine kinase domain of epidermal growth factor
      receptor (EGFR) have been characterized in a subset of patients with advanced NSCLC.The EGFR
      mutation rate was 30% in Chinese Non-small Cell Lung Cancer(NSCLC). Patients harboring these
      mutations in their tumors show excellent response to EGFR tyrosine kinase inhibitors
      (EGFR-TKIs). This randomized phase III trial is studying gefitinib to see how well it works
      compared to cisplatin-based chemotherapy in treating patients who have undergone surgery for
      stage II-IIIA(N1-N2) NSCLC with EGFR activating mutation in Asian population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adjuvant cisplatin-based chemotherapy is recommended for routine use in patients with stages
      IIA, IIB, and IIIA non-small cell lung cancer (NSCLC) after complete resection. Cisplatin and
      vinorelbine combination is the standard of care in adjuvant setting. The BR. 19 trial
      reported adjuvant gefitinib after complete resection of early stage NSCLC(stage IB 49%, II
      38%, III 13%) did not confer disease free survival(DFS) or overall survival(OS) advantage in
      overall population. While the median gefitinib treatment time is only 4.8 months. There are
      only 76 patients with EGFR mutations included in this analysis. The study closed prematurely
      in 2005.

      Activating somatic mutations of the tyrosine kinase domain of epidermal growth factor
      receptor (EGFR) have been characterized in a subset of patients with advanced NSCLC.The EGFR
      mutation rate was 30% in Chinese NSCLC. Patients harboring these mutations in their tumors
      show excellent response to EGFR tyrosine kinase inhibitors (EGFR-TKIs). This randomized phase
      III trial is studying gefitinib to see how well it works compared to cisplatin-based
      chemotherapy in treating patients who have undergone surgery for stage II-IIIA(N1-N2) NSCLC
      with EGFR activating mutation in Asian population.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>Pts after surgery will receive long-term follow-up including chest CT scan, abdominal ultrasound every 3 months, brain MRI every 6 months, bone scan every 12 months for up to 3 years. The survival after 3 years will be followed up with telephone.</time_frame>
    <description>To evaluate the disease free survival of gefitinib versus combination of vinorelbine plus platinum as adjuvant treatment for pathological stage II-IIIA(N1-N2) NSCLC with EGFR mutation.Disease free survival (DFS)- defined as the time from randomization to the first documented disease progression or death, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Pts after surgery will receive long-term follow-up including chest CT scan, abdominal ultrasound every 3 months, brain MRI every 6 months, bone scan every 12 months for up to 3 years. The survival after 3 years will be followed up with telephone.</time_frame>
    <description>To evaluate the overall survival of gefitinib versus combination of vinorelbine plus platinum as adjuvant treatment for stage II-IIIA(N1-N2) NSCLC with EGFR mutation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 yeas DFS rate, 5 years DFS rate, 5 years OS rate</measure>
    <time_frame>Pts after surgery will receive long-term follow-up including chest CT scan, abdominal ultrasound every 3 months, brain MRI every 6 months, bone scan every 12 months for up to 3 years. The survival after 3 years will be followed up with telephone.</time_frame>
    <description>To compare the randomized treatment arms in terms of 3 yeas DFS rate, 5 years DFS rate, 5 years OS rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>In the period of Gefitinib 250 mg/day oral daily for 24 months.Vinorelbine 25 mg/m2 intravenous infusion on day 1 and day 8, Cisplatin 75 mg/m2 on day 1 for 4 cycles.</time_frame>
    <description>The safety and tolerability profile of gefitinib at a 250 mg daily dose relative to that of Chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>In the period of Gefitinib 250 mg/day oral daily for 24 months.Vinorelbine 25 mg/m2 intravenous infusion on day 1 and day 8, Cisplatin 75 mg/m2 on day 1 for 4 cycles.</time_frame>
    <description>Quality of life as measured by the total score and Trial Outcome Index (TOI) of the Functional Assessment of Cancer Therapy - Lung Cancer (FACT-L) questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">222</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Gefitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gefitinib 250 mg/day oral daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vinorelbine+Cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vinorelbine 25 mg/m2 intravenous infusion on day 1 and day 8, Cisplatin 75 mg/m2 on day 1 for 4 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
    <description>Gefitinib 250 mg/day oral daily</description>
    <arm_group_label>Gefitinib</arm_group_label>
    <other_name>Iressa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine+Cisplatin</intervention_name>
    <description>Vinorelbine 25 mg/m2 intravenous infusion on day 1 and day 8, Cisplatin 75 mg/m2 on day 1 for 4 cycles</description>
    <arm_group_label>Vinorelbine+Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent provided.

          -  Males or females aged ≥18 years, &lt; 75 years.

          -  Able to comply with the required protocol and follow-up procedures, and able to
             receive oral medications.

          -  Target population is completely resected pathological stage II-IIIA(N1-N2) NSCLC with
             EGFR exon 19 deletions and exon 21 L858R activating mutation.

          -  Patient who can start the investigational therapy within 3-6 weeks after the complete
             resection

          -  ECOG performance status 0-1.

          -  Life expectancy ≥12 weeks.

          -  Adequate hematological function: Absolute neutrophil count (ANC) ≥2.0 x 109/L, and
             Platelet count ≥100 x 109/L, and Hemoglobin ≥9 g/dL (may be transfused to maintain or
             exceed this level).

          -  Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN),
             Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 x ULN in
             subjects without liver metastases; ≤ 5 x ULN in subjects with liver metastases.

          -  Adequate renal function: Serum creatinine ≤ 1.25 x ULN, or ≥ 60 ml/min.

          -  Female subjects should not be pregnant or breast-feeding.

        Exclusion Criteria:

          -  Known severe hypersensitivity to gefitinib or any of the excipients of this product.

          -  Known severe hypersensitivity to pre-medications required for treatment with cisplatin
             / vinorelbine doublet chemotherapy.

          -  Inability to comply with protocol or study procedures.

          -  A serious concomitant systemic disorder that, in the opinion of the investigator,
             would compromise the patient's ability to complete the study.

          -  A serious cardiac condition, such as myocardial infarction within 6 months, angina, or
             heart disease.

          -  Interstitial pneumonia.

          -  Patients with prior exposure to agents directed at the HER axis (e.g. erlotinib,
             gefitinib, cetuximab, trastuzumab).

          -  Patients with prior chemotherapy or therapy with systemic anti-tumour therapy (e.g.
             monoclonal antibody therapy).

          -  Patients with prior radiotherapy

          -  History of another malignancy in the last 5 years with the exception of the
             following:Other malignancies cured by surgery alone and having a continuous
             disease-free interval of 5 years are permitted. Cured basal cell carcinoma of the skin
             and cured in situ carcinoma of the uterine cervix are permitted.

          -  Any unstable systemic disease (including active infection, uncontrolled hypertension,
             unstable angina, congestive heart failure, myocardial infarction within the previous
             year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic
             disease).

          -  Eye inflammation or eye infection not fully treated or conditions predisposing the
             subject to this.

          -  Evidence of any other disease, neurological or metabolic dysfunction, physical
             examination or laboratory finding giving reasonable suspicion of a disease or
             condition that contraindicated the use of an investigational drug or puts the subject
             at high risk for treatment-related complications.

          -  Patient who has active serious infection (e.g. pyrexia of or 38.0℃ over)

          -  Patients who harbouring exon 20 T790M mutation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi-Long WU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xue-Ning YANG, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Guangdong General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wen-Zhao ZHONG, MD</last_name>
    <role>Study Director</role>
    <affiliation>Guangdong General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Janjigian YY, Park BJ, Zakowski MF, Ladanyi M, Pao W, D'Angelo SP, Kris MG, Shen R, Zheng J, Azzoli CG. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. J Thorac Oncol. 2011 Mar;6(3):569-75. doi: 10.1097/JTO.0b013e318202bffe.</citation>
    <PMID>21150674</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2011</study_first_submitted>
  <study_first_submitted_qc>July 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2011</study_first_posted>
  <last_update_submitted>June 5, 2017</last_update_submitted>
  <last_update_submitted_qc>June 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangdong Association of Clinical Trials</investigator_affiliation>
    <investigator_full_name>Yi-Long Wu</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Lung cancer</keyword>
  <keyword>II-IIIA(N1-N2)</keyword>
  <keyword>Adjuvant treatment</keyword>
  <keyword>EGFR mutations</keyword>
  <keyword>Tyrosine kinase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

